Target intelligence / Profile preview

Eukaryotic translation initiation factor 2B subunit gamma (EIF2B3)

Target
EIF2B3
Molecular classification
Enzyme (specifically, guanine nucleotide exchange factor), Translation factor
01

Overview

Eukaryotic translation initiation factor 2B subunit gamma (EIF2B3) is a core component of the eIF2B complex, which serves as a guanine nucleotide exchange factor essential for recycling eIF2-bound GDP to GTP—a critical step for the initiation phase of mRNA translation in eukaryotic cells. EIF2B3 forms part of a multisubunit complex that regulates overall protein synthesis and modulates the integrated cellular stress response. Mutations in EIF2B3 are strongly implicated in vanishing white matter (VWM) disease, a severe neurodegenerative disorder characterized by progressive loss of central nervous system myelin. EIF2B3 also participates in specialized translation mechanisms, such as internal ribosome entry in viral infections, and contributes to proper glial cell differentiation and white matter integrity. The gene is widely expressed, especially in the brain and glial cells, reflecting its fundamental role in neurobiology

Other names
Translation initiation factor eIF2B subunit gammaEIF2BgammaEIF-2BeIF2B GDP-GTP exchange factor subunit gammaVWM3eIF-2B GDP-GTP exchange factor subunit gammaeif2b3eukaryotic translation initiation factor 2B, subunit 3 gamma58kDa
02

Mechanism of action

None established for approved drugs; theoretical mechanisms include modulation of eIF2B-mediated guanine nucleotide exchange to influence translation initiation and stress response pathways

03

Biological functions

Guanine nucleotide exchange on eukaryotic initiation factor 2 (eIF2)Regulation of translation initiationIntegrated stress response modulation
04

Disease associations

Neurodegenerative diseases (notably, Vanishing White Matter disease / leukoencephalopathy with vanishing white matter)Modifier of age-at-onset in Parkinson diseaseOther (potential cofactor in viral translation, e.g., hepatitis C)
05

Safety considerations

Therapeutic targeting of translation initiation carries risk of widespread inhibition of protein synthesis, especially in neurons and glia, potentially causing neurotoxicity and impairing tissue regeneration
06

Biomarkers

Mutations in EIF2B3 are used for diagnosis of vanishing white matter disease and as genetic biomarkers in leukodystrophies

Beyond the preview

Go deeper on Eukaryotic translation initiation factor 2B subunit gamma (EIF2B3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eukaryotic translation initiation factor 2B subunit gamma (EIF2B3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call